Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Abroad (travel likely)RecruitingPHASE2

Conditions

Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · CLL Variant

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Cincinnati, Cincinnati, Ohio, United States
Contact: Study coordinator (Christine Vollmer) · mccordce@ucmail.uc.edu · 5132133203
Contact: Principal Investigator (Zulfa Omer, MD)

Study leads

Zulfa Omer
Principal Investigator
University of Cincinnati

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Beijing, China

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)

Abroad (travel likely)RecruitingPHASE2

Concord, Australia · Kogarah, Australia

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

CLL · Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE3

Jonesboro, United States · Los Angeles, United States